EG-70 (phase 2) clinical trials

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study is testing a new gene therapy, EG-70, for bladder cancer that hasn't responded to standard treatments. It aims to see how safe and effective it is for different types of non-muscle invasive bladder cancer.